91 related articles for article (PubMed ID: 10037020)
1. Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?
Schultze JL
Leuk Lymphoma; 1999 Jan; 32(3-4):223-36. PubMed ID: 10037020
[TBL] [Abstract][Full Text] [Related]
2. T cell mediated immunotherapy for B cell lymphoma.
Schultze JL; Nadler LM
J Mol Med (Berl); 1999 Mar; 77(3):322-31. PubMed ID: 10090595
[TBL] [Abstract][Full Text] [Related]
3. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.
Yang ZZ; Liang AB; Ansell SM
Leuk Lymphoma; 2015; 56(9):2498-504. PubMed ID: 25651421
[TBL] [Abstract][Full Text] [Related]
4. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
5. Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma.
Prato S; Mintern JD; Lahoud MH; Huang DC; Villadangos JA
Immunol Cell Biol; 2011 Jul; 89(5):595-603. PubMed ID: 21079642
[TBL] [Abstract][Full Text] [Related]
6. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
9. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.
Chaperot L; Jacob MC; Molens JP; Manches O; Bensa JC; Plumas J
Leuk Lymphoma; 2000 Jul; 38(3-4):247-63. PubMed ID: 10830732
[TBL] [Abstract][Full Text] [Related]
10. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
11. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.
Flamand V; Sornasse T; Thielemans K; Demanet C; Bakkus M; Bazin H; Tielemans F; Leo O; Urbain J; Moser M
Eur J Immunol; 1994 Mar; 24(3):605-10. PubMed ID: 8125131
[TBL] [Abstract][Full Text] [Related]
12. Biologic response modifiers in acute lymphoblastic leukemia.
Gribben JG; Cardoso AA; Schultze JL; Nadler LM
Leukemia; 1997 May; 11 Suppl 4():S31-3. PubMed ID: 9179280
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
14. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
[TBL] [Abstract][Full Text] [Related]
15. Developing T cell cancer immunotherapy in the dog with lymphoma.
O'Connor CM; Wilson-Robles H
ILAR J; 2014; 55(1):169-81. PubMed ID: 24936037
[TBL] [Abstract][Full Text] [Related]
16. A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines.
Felsher DW; Rhim SH; Braun J
Cancer Res; 1990 Nov; 50(21):7050-6. PubMed ID: 2208172
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of T-lymphocytes infiltrating human B-cell lymphomas.
Marquardt P; Müller-Hermelink HK
Environ Health Perspect; 1990 Aug; 88():233-5. PubMed ID: 2148723
[TBL] [Abstract][Full Text] [Related]
18. Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning.
Rubio MT; Zhao G; Buchli J; Chittenden M; Sykes M
Clin Immunol; 2006 Jul; 120(1):33-44. PubMed ID: 16675304
[TBL] [Abstract][Full Text] [Related]
19. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
20. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
